Metraipolis › archive › dc_ce977fb283c0

Predicting Chemotherapy Response in Triple-Negative Breast Cancer: The Role of CYP2Cs as a Biomarker and a Drug Target (A Proof-of-Concept Study) — Europe PMC PMID:42943202

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42943202
DOI
10.3390/ph19101501
License (as archived)
solo-consultazione
Archived
2026-10-31T09:17:42.702Z
SHA-256 of the archived text
1b3cdfe225019d6e7fd2ac07676397fdba6e83ff56519817c1e166fc7207ff83
Stable URL of this page
https://metraipolis.com/documento/dc_ce977fb283c0

How to cite

Predicting Chemotherapy Response in Triple-Negative Breast Cancer: The Role of CYP2Cs as a Biomarker and a Drug Target (A Proof-of-Concept Study) — Europe PMC PMID:42943202 — Europe PMC (en), https://europepmc.org/article/MED/42943202 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ce977fb283c0 (Metraipolis archive dc_ce977fb283c0, sha256 1b3cdfe225019d6e7fd2ac07676397fdba6e83ff56519817c1e166fc7207ff83)
BibTeX
@misc{dcce977fb283c0,
  title = {Predicting Chemotherapy Response in Triple-Negative Breast Cancer: The Role of CYP2Cs as a Biomarker and a Drug Target (A Proof-of-Concept Study) — Europe PMC PMID:42943202},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42943202},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ce977fb283c0; sha256 1b3cdfe225019d6e7fd2ac07676397fdba6e83ff56519817c1e166fc7207ff83},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42943202. Agents can read the archived copy with the MCP tool read_document.